Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 303

Sort by

Sort Order Select

Journal Articles

Impact of Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas

Blood blood.2023021187.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Blood (2022) 140 (Supplement 1): 8092–8093.

https://doi.org/10.1182/blood-2022-164617

Published: 2022

Journal Articles

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7141–7143.

https://doi.org/10.1182/blood-2022-163746

Published: 2022

Journal Articles

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Reyka G. Jayasinghe, George Mulligan, April Cook, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn J. Cho, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 7090–7091.

https://doi.org/10.1182/blood-2022-167462

Published: 2022

Journal Articles

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10942–10944.

https://doi.org/10.1182/blood-2022-164785

Published: 2022

Journal Articles

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Blood (2022) 140 (Supplement 1): 10068–10070.

https://doi.org/10.1182/blood-2022-162754

Published: 2022

Journal Articles

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Salyka M. Sengsayadeth, Bridget Fitzgerald, Bharat Nandakumar, Bicky Thapa, Timothy Martin Schmidt, Rebecca Silbermann, Heidi Chen, Saurabh Chhabra, Natalie Callander, Shaji K Kumar, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10033–10035.

https://doi.org/10.1182/blood-2022-169589

Published: 2022

Journal Articles

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Mohamed A Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Eva Doelger, Edyta Dobkowska, Shaji K Kumar, Weize Huang, Rajeev Menon, Ahmed Hamed Salem

Blood (2022) 140 (Supplement 1): 4281–4282.

https://doi.org/10.1182/blood-2022-166584

Published: 2022

Journal Articles

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Radhika Bansal, Sikander Ailawadhi, Jeremy T. Larsen, Morie A Gertz, Matthew A. Hathcock, David Dingli, Prashant Kapoor, Taxiarchis Kourelis, Suzanne R. Hayman, Rahma M Warsame, Moritz Binder, Ricardo D Parrondo, Rafael Fonseca, P. Leif Bergsagel, Shaji K Kumar, Yi Lin

Blood (2022) 140 (Supplement 1): 1862–1864.

https://doi.org/10.1182/blood-2022-166662

Published: 2022

Journal Articles

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Eli Muchtar, Surendra Dasari, Martha Grogan, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Taxiarchis Kourelis, Itzhak Z. Attia, Francisco Lopez-Jimenez, Dennis Murphree, Paul A. Friedman, Shaji K Kumar, Angela Dispenzieri

Blood (2022) 140 (Supplement 1): 7230–7232.

https://doi.org/10.1182/blood-2022-168119

Published: 2022

Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar

Blood (2022) 140 (Supplement 1): 4620–4622.

https://doi.org/10.1182/blood-2022-158231

Published: 2022

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2347–2348.

https://doi.org/10.1182/blood-2022-167430

Published: 2022

Journal Articles

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria

Blood (2022) 140 (Supplement 1): 4444–4446.

https://doi.org/10.1182/blood-2022-157713

Published: 2022

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Blood (2022) 140 (Supplement 1): 10142–10143.

https://doi.org/10.1182/blood-2022-169046

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Linda B. Baughn, Elizabeth S. Mearns, Michael Nixon, Vivek S. Chopra, Allicia Girvan, R. Frank Cornell, Jayeta Saxena, Bethany M. Slifko, Jordan Clark, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 10114–10115.

https://doi.org/10.1182/blood-2022-158076

Published: 2022

Journal Articles

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Neeraj Sharma, Hongwei Tang, Huihuang Yan, Shulan Tian, Suganti Shivaram, Taxiarchis Kourelis, Shaji K Kumar, Linda B. Baughn

Blood (2022) 140 (Supplement 1): 4209–4210.

https://doi.org/10.1182/blood-2022-166744

Published: 2022

NARROW

Impact of Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only